Vaughan David Investments LLC IL Purchases 4,569 Shares of Abbott Laboratories (NYSE:ABT)

Vaughan David Investments LLC IL grew its position in Abbott Laboratories (NYSE:ABTFree Report) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 423,184 shares of the healthcare product maker’s stock after acquiring an additional 4,569 shares during the period. Abbott Laboratories comprises about 1.3% of Vaughan David Investments LLC IL’s portfolio, making the stock its 23rd largest holding. Vaughan David Investments LLC IL’s holdings in Abbott Laboratories were worth $46,580,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ABT. Halpern Financial Inc. bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $26,000. Altshuler Shaham Ltd bought a new stake in shares of Abbott Laboratories during the 4th quarter worth about $28,000. Cornerstone Planning Group LLC bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth about $28,000. CGC Financial Services LLC bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth about $32,000. Finally, FWL Investment Management LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter worth about $33,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE:ABT traded down $2.35 during midday trading on Friday, hitting $109.10. The stock had a trading volume of 4,041,536 shares, compared to its average volume of 5,581,388. The company’s 50-day moving average price is $114.78 and its 200-day moving average price is $107.20. The company has a market capitalization of $189.31 billion, a P/E ratio of 34.18, a price-to-earnings-growth ratio of 2.68 and a beta of 0.74. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.35. Abbott Laboratories has a fifty-two week low of $89.67 and a fifty-two week high of $121.64.

Abbott Laboratories (NYSE:ABTGet Free Report) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.19. The business had revenue of $10.24 billion during the quarter, compared to analysts’ expectations of $10.19 billion. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.03 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.02%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is 67.48%.

Insider Buying and Selling

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the sale, the vice president now directly owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $55,932.00. Following the completion of the transaction, the vice president now directly owns 18,760 shares in the company, valued at approximately $2,223,060. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 963 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $114,115.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The disclosure for this sale can be found here. Insiders sold a total of 56,435 shares of company stock worth $6,451,298 in the last three months. 1.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently commented on ABT. Raymond James lifted their target price on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Barclays lifted their price objective on shares of Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. Evercore ISI lifted their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Citigroup lifted their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b-” rating in a research note on Thursday, December 21st. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.14.

Check Out Our Latest Research Report on ABT

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Featured Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTFree Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.